[ PAPER ] · 2023 · Annals of Allergy, Asthma & Immunology
Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations.
Derek K. Chu, Lynda C. Schneider, R. Asiniwasis, M. Boguniewicz, A. de Benedetto, Kathy Ellison, Winfred Frazier, M. Greenhawt, Joey Huynh, Elaine Kim, J. LeBovidge, M. Lind, P. Lio, Stephen A. Martin, Monica O’Brien, P. Ong, J. Silverberg, J. Spergel, Julie Wang, K. Wheeler, G. Guyatt, K. Capozza, W. Begolka, A. Chu, I. Zhao, Lina Chen, P. Oykhman, L. Bakaa, D. Golden, Marcus S. Shaker, Jonathan A. Bernstein, C. Horner, Jay A. Lieberman, D. Stukus, M. Rank, Anne K. Ellis, E. Abrams, D. Ledford, Derek K. Chu
[ TLDR ]
These evidence-based recommendations address optimal use of topical and systemic treatments for atopic dermatitis for patients with mild, moderate, and severe AD.
[ ABSTRACT ]
BACKGROUND Guidance addressing atopic dermatitis (AD) management, last issued in 2012 by the American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force, requires updating as a result of new treatments and improved guideline and evidence synthesis methodology. OBJECTIVE To produce evidence-based guidelines that support patients, clinicians, and other decision-makers in the optimal treatment of AD. METHODS A multidisciplinary guideline panel consisting of patients and caregivers, AD experts (dermatology and allergy/immunology), primary care practitioners (family medicine, pediatrics, internal medicine), and allied health professionals (psychology, pharmacy, nursing) convened, prioritized equity, diversity, and inclusiveness, and implemented management strategies to minimize influence of conflicts of interest. The Evidence in Allergy Group supported guideline development by performing systematic evidence reviews, facilitating guideline processes, and holding focus groups with patient and family partners. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach informed rating the certainty of evidence and strength of recommendations. Evidence-to-decision frameworks, subjected to public comment, translated evidence to recommendations using trustworthy guideline principles. RESULTS The panel agreed on 25 recommendations to gain and maintain control of AD for patients with mild, moderate, and severe AD. The eAppendix provides practical information and implementation considerations in 1-2 page patient-friendly handouts. CONCLUSION These evidence-based recommendations address optimal use of (1) topical treatments (barrier moisturization devices, corticosteroids, calcineurin inhibitors, PDE4 inhibitors [crisaborole], topical JAK inhibitors, occlusive [wet wrap] therapy, adjunctive antimicrobials, application frequency, maintenance therapy), (2) dilute bleach baths, (3) dietary avoidance/elimination, (4) allergen immunotherapy, and (5) systemic treatments (biologics/monoclonal antibodies, small molecule immunosuppressants [cyclosporine, methotrexate, azathioprine, mycophenolate, JAK inhibitors], and systemic corticosteroids) and UV phototherapy (light therapy).